News AbbVie's migraine drug cleared for migraine attacks on NHS AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.
News Cancer biotech Parabilis books record IPO, raising $670m Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.
News Sanofi abandons phase 3 trial of neurology drug riliprubart Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.
News Moderna jab on trial for cancer-causing syndrome Patients with Lynch syndrome could have a potential treatment on the horizon, as a Moderna mRNA vaccine starts trials at Oxford University.
News Jen Norton appointed market access leader at EVERSANA EVERSANA has named Jen Norton as president of its recently formed Market Access & Value division.
News Most doctors in UK think AI training is inadequate A survey has shown that UK doctors think AI can help them save time and expand their capacity to care for patients, but training is lacking.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.